【レポートの概要(一部)】
1. Report Overview
1.1 Epigenetic Therapies, Technologies and Diagnostics: World Market Review
1.2 Global Epigenetics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Main Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Epigenetics and Uses in Pharma
2.1 How is Epigenetics Defined?
2.1.1 Epigenetic Mechanisms
2.1.2 A Brief History of Epigenetic Research
2.2 The Links between Epigenetics and Disease
2.2.1 The Role of Lifestyle in Epigenetics
2.2.2 Epigenetics and Cancer
2.2.3 Epigenetics in Inherited Disorders
2.2.4 Epigenetics in Neurological Diseases
2.3 Epigenetics in Disease Diagnosis
2.3.1 Diagnosing for Breast Cancer
2.3.2 Colorectal Cancer: The Importance of Early Diagnosis
2.3.3 Diagnostics for Lung Cancer: Difficulty in Accessing Samples
2.3.4 Diagnostics for Prostate Cancer
2.4 The Use of Epigenetics in Treating Diseases
2.4.1 DNA Methlytransferase (DNMT) Inhibitors
2.4.1.1 Myelodysplastic Syndrome (MDS)
2.4.2 Histone Deacetylase (HDAC) Inhibitors
2.4.2.1 Cutaneous T Cell Lymphoma (CTCL)
2.4.2.2 Peripheral T Cell Lymphoma (PTCL)
2.5 Drug Discovery and Development Tools Using Epigenetics
2.5.1 Bisulphite Screening for DNA Methylation
2.5.2 Chromatin Immunoprecipitation (ChIP) for Histone Modification
3. The Global Epigenetic Therapies, Technologies and Diagnostics Market 2014-2024
3.1 The Global Epigenetic Therapies, Technologies and Diagnostics Market in 2013
3.1.1 Leading Segments of the Market in 2013
3.2 The Epigenetic Therapies, Technologies and Diagnostics Global Market 2014-2024
3.2.1 The Epigenetic Therapies, Technologies and Diagnostics Global Market: Revenue Forecasts 2014-2024
3.2.2 What Will Expedite the Growth of Epigenetic Therapies, Technologies and Diagnostics Market?
3.2.3 Increase in Epigenetic Diagnostics Market Share 2014-2024
3.3 Epigenetic Therapies Submarket 2014-2024
3.3.1 Epigenetic Therapies Submarket: Revenue Forecast 2014-2024
3.3.2 Rising Importance of Epigenetic Therapies Revenue 2014-2024
3.4 Epigenetic Technologies Submarket 2014-2024
3.4.1 Epigenetic Technologies Submarket: Revenue Forecast 2014-2024
3.4.2 Epigenetic Technologies Submarket: Drivers and Restraints 2014-2024
3.5 Epigenetic Diagnostics Submarket 2014-2024
3.5.1 Epigenetic Diagnostics Submarket: Revenue Forecast 2014-2024
3.5.2 Growth Driving Factor: New Product Launches 2014-2024
4. Leading National Epigenetic Therapies, Technologies and Diagnostics Markets 2014-2024
4.1 Leading National Markets for Epigenetic Therapies, Technologies and Diagnostics 2013
4.2 Leading National Markets: Revenue Forecasts 2014-2024
4.2.1 Global Market Will Be Dominated by the Western Countries 2014-2024
4.3 The Northern American Market 2014-2024
4.3.1 The US: The World’s Largest Market for the Epigenetic Therapies, Technologies and Diagnostics 2014-2024
4.3.2 Canada: Revenue Forecast 2014-2024
4.4 European Union (EU) Epigenetics Market: Revenues 2013
4.4.1 Leading National Markets in EU: Revenue Forecasts 2014-2024
4.4.2 Germany: Revenue Forecast 2014-2024
4.4.3 The UK: A Leading Country for Epigenetic Research
4.5 Japanese Market: Increased Interest in Epigenetics
4.6 Epigenetics in Emerging National Markets
4.6.1 BRIC Nations: Positive Growth Expected in Epigenetic Therapies, Technologies and Diagnostics Markets 2014-2024
5. Epigenetic Therapies Market 2014-2024
5.1 The Future of the Epigenetic Therapies Market 2014-2024
5.2 Vidaza (Celgene Co. / Nippon Shinyaku): The First Therapy in the Epigenetic Market
5.2.1 Vidaza: Leading Epigenetic Therapy 2004-2012
5.2.2 How Was Vidaza Affected by Patent Expiry?
5.2.3 Will Oral Azacitidine and Combination Therapy Stimulate Vidaza Growth?
5.2.4 Vidaza: Revenue Forecast 2014-2024
5.3 Dacogen (Eisai/ Janssen-Cilag/ Otsuka Pharmaceutical Co.)
5.3.1 Dacogen: Historical Revenue Performance 2006-2012
5.3.2 EU Approval and Combination Therapy to Drive Sales Growth?
5.3.3 Will Oral Azacitidine and Combination Therapy Drive Vidaza Growth?
5.3.4 Dacogen: Revenue Forecast 2014-2024
5.4 Zolinza (Merck & Co./ Taiho Pharmaceutical)
5.4.1 Zolinza for Multiple Myeloma Treatment
5.4.2 Zolinza Revenue Forecast 2014-2024
5.5 Istodax: Second Epigenetic Drug by Celgene Co.
5.5.1 Istodax: Strong Revenue Growth 2010-2011
5.5.2 International Market Approvals to Drive Growth?
5.5.3 Istodax: Revenue Forecast 2014-2024
5.6 Epigenetic Therapy Market 2013: Rich Pipeline for HDAC Inhibitors
5.6.1 Beleodaq (TopoTarget/ Spectrum Pharmaceuticals): A Novel HDAC Inhibitor
5.6.2 Faridak (Novartis): Treatment for Velcade-Refractory Multiple Myeloma
5.6.3 Entinostat (Syndax Pharmaceuticals, Inc.): Breast and Lung Cancer
5.6.4 Resminostat (4SC/ Yakult Honsha Co.): Hepatocellular Carcinoma
5.6.5 Pracinostat (MEI Pharma): Treatment for MDS and AML
5.6.6 Mocetinostat: Initiatives of Mirati Therapeutics to Drive Development
5.6.7 Quisinostat (Janssen Pharmaceutica, NV/ NewVac LLC)
5.6.8 Rocilinostat (Acetylon Pharmaceuticals): One of Celgene’s Keen Interest
5.6.9 CHR-3396 (Chroma Therapeutics)
5.6.10 Givinostat (Italfarmaco): Chronic Myeloproliferative Neoplasms and Duchenne Muscular Dystrophy
5.6.11 Shape (TetraLogic Pharmaceuticals): The First Topical HDAC inhibitor for CTCL
5.6.12 FRM-0334 (Forum Pharmaceuticals Inc): Neurodegenerative Diseases
5.6.13 4SC-202: Second Epigenetic Drug by 4SC Has Potential for Wider Indications
5.6.14 Tefinostat (Chroma Therapeutics): Haematological Cancer
5.6.15 CDX10 (Celleron Therapeutics): Part of Personalised Cancer Treatment Trial
5.6.16 RG2833 (The Scripps Research Institute): Friedreich’s Ataxia
5.6.17 Abexinostat (Pharmacyclics)
5.7 New Discoveries in the Field of HDAC 2013
5.7.1 Chemogenic Approaches to Spatiotemporal Regulation of HDAC Activity
5.7.2 Novel Lysine Pathways and Acetylation-Independent Mechanisms of HDACs
5.7.3 HDAC Inhibitor: Treatment of Pathological Muscle Remodelling
5.7.4 Design of Class I Isoform Selective Inhibitors for Use in Metabolic Indications
5.7.5 Zinc Binding Groups Inhibit Class IIa HDAC and Alters Immune Responses
5.8 DNMT Inhibitor R&D Pipeline 2013
5.8.1 SGI-110 (Otsuka Pharmaceuticals): A Second Generation DNMT Inhibitor
5.8.2 FdCyd (National Cancer Institute): Solid Tumours
5.8.3 Hydralazine: Being Tested in 23 Clinical Trials
5.8.4 MG98 (Mirati Therapeutics)
5.8.5 CP-4200: A Second Generation Vidaza
5.8.6 RX3117 (Rexahn Pharmaceuticals)
5.9 Pipeline Treatments Targeting Other Epigenetic Enzymes 2013
5.9.1 EPZ-5676 (Epizyme Inc./ Celgene Co.): The First Clinical-Stage HMT Inhibitor
5.9.2 EPZ-5676 (Epizyme Inc./ Eisai): The Second Clinical-Stage HMT Inhibitor
5.9.3 ORY-1001(Roche): Orphan Drug Status in Early Stage AML
5.9.4 SP-2528 (Salarius Pharmaceuticals)
5.9.5 RVX-208 (Resverlogix): Advancing BET Protein Inhibitors
5.10 MiRNA Therapy Pipeline 2013
5.10.1 Miravirsen (Santaris Pharma A/S): The First miRNA Therapy to Enter Human Clinical Trial
5.10.2 MRX34 (Mirna Therapeutics)
5.10.3 Collaborations of Regulus Therapeutics with Big Pharma Players
5.11 Leading Epigenetic Therapy Manufacturers and Developers
5.11.1 Celgene: Market Leader in 2013
5.11.2 Eisai
5.11.3 Janssen-Cilag
5.11.4 Otsuka Pharmaceuticals
5.11.5 Merck & Co.
5.11.6 TopoTarget to Merge with BioAlliance Pharma SA
5.11.7 Syndax Pharmaceuticals
5.11.8 4SC
5.11.9 Curis: Focusing on Multi-Targeted Treatments
5.11.10 CellCentric: Collaborating with Big Pharma for Drug Development
5.11.11 Constellation Pharmaceuticals
5.11.12 EpiTherapeutics
5.11.13 Epizyme: Signed Multiple Collaboration Agreements with Big Pharma
5.11.14 IkerChem: HDAC and DNMT Inhibitors in Cancer and CNS Disorders
5.11.15 Karus Therapeutics: HDAC Inhibitors for Inflammatory Diseases and Cancer
6. Epigenetic Technologies: Markets 2014-2024
6.1 Epigenetic Technologies and Services Market 2014-2024
6.1.1 Should Epigenetic Discovery and Analysis Be Outsourced?
6.2 Next Generation Sequencing (NGS)
6.2.1 Higher Speed and Reduced Costs for Epigenetic Research
6.2.2 Are Current Bioinformatic Programmes a Setback?
6.2.3 Single Molecule Sequencing to Compete with NGS
6.3 The Future of Chromatin Immunoprecipitation
6.3.1 ChIP-Seq
6.4 Future Developments in Bisulphite Screening
6.4.1 Importance of Techniques to Distinguish 5hmC
6.5 High Throughput Screening
6.6 Leading Providers of Epigenetics Technologies 2013
6.6.1 Active Motif
6.6.2 Measurement Tools for Epigenetic Research by Agilent Technologies
6.6.3 Diagenode: Best –In-Class Methyl Binding Domain Based Kit
6.6.4 DiscoveRx
6.6.5 EMD Millipore
6.6.6 Epigenetek: Specialist in Epigenetic Technologies
6.6.7 Epiontis: Assessing Purity in Regenerative Medicine Products
6.6.8 Life Technologies: Reducing NGS Process Cost
6.6.9 Qiagen: Epigenetic Technologies and Diagnostics
6.6.10 Roche
7. Epigenetic Diagnostics Market 2014-2024
7.1 Development of the Epigenetic Diagnostics Market 2014-2024
7.1.1 LDTs vs. IVDs: Two Diagnostics Development Strategies
7.2 Epigenetic Diagnostics Market 2013
7.2.1 Epi proColon 2.0 (Epigenomics)
7.2.2 ColoVantage (Quest Diagnostics)
7.2.3 Septin9 LDT (ARUP Laboratories)
7.2.4 ColoSure (LabCorp)
7.2.5 ConfirmMDx for Prostate Cancer
7.2.6 Gene Methylation in Prostate Cancer (LabCorp)
7.2.7 Epi proLung (Epigenomics)
7.2.8 MGMT Gene Methylation Assay (LabCorp)
7.2.9 PredictMDx (MDxHealth): Brain Cancer
7.2.10 Bladder Cancer Testing with CertNDx (Physician’s Choice Laboratory Services)
7.3 Epigenetic Diagnostics R&D Pipeline 2013
7.3.1 The Future of Colorectal Cancer Testing
7.3.1.1 Cologuard: Improved Sensitivity
7.3.1.2 Orion Colorectal Cancer Risk Test (Orion Genomics)
7.3.2 Pipeline of Prognostic Tools for Prostate Cancer
7.3.3 Lung Cancer
7.3.3.1 Lung Cancer Screening Test (Orion Genomics)
7.3.3.2 ConfirmMDx and InformMDx (MDxHealth)
7.3.4 The Future of Bladder Cancer Testing
7.3.4.1 Bladder Cancer Screening Test (Orion Genomics)
7.3.5 Other Cancer Tests Pipeline 2013
7.3.5.1 Pancreatic Cancer Prognostic Test (PrognosticDx Health)
7.4 Leading Epigenetic Diagnostic Developers 2013
7.4.1Epigenomics: Multiple Tests Marketed in the EU
7.4.1.1 Positive Revenue Growth 2012-2013
7.4.2 Exact Sciences: Colorectal Cancer Screening
7.4.3 MDxHealth: Targeting the US Diagnostics Markets
7.4.3.1 Strong Revenue Growth 2009-2013
7.4.4 Orion Genomics: More than 100 Markers Have Been Discovered
7.4.5 Physician’s Choice Laboratory Services (PCLS)
7.4.6 PrognosDx Health: Developing Epigenetic Prognostics
8. Research and Product Development Strategies in Epigenetics 2014
8.1 Epigenetics Therapies, Technologies and Diagnostics Market by Disease 2014-2024
8.2 Present and Future Epigenetic Research in Cancer
8.2.1 Twin Studies Reveal Epigenetic Biomarkers in Breast Cancer
8.2.2 Colorectal Cancer: More Than Two Biomarkers Established
8.2.3 Lung Cancer: Prognostic Markers
8.2.4 Prostate Cancer: The Need for Progression in Epigenetic Therapies
8.3 The Role of DNA Hypomethylation in Autoimmune Diseases
8.3.1 Lupus
8.3.2 Rheumatoid Arthritis as a Target for Drugs and Diagnostics
8.3.2.1 Ignyta: Pioneer in Epigenetic Diagnostic for Rheumatoid Arthritis
8.3.3 Prevalence of Diabetes linked to Diet and Ageing
8.4 Neurodegenerative Diseases
8.4.1 Alzheimer’s Disease: Symptoms Improved with HDAC Inhibitors
8.4.2 Huntington’s Disease: Epigenetic Drugs in Clinical Development
8.5 Neurological Disorders
8.5.1 Drug Resistance in Schizophrenia
8.5.2 Hundreds of Genetic and Epigenetic Mutations linked to Autism
8.6 New Epigenetic Therapy Targets
8.6.1 BET Proteins Targeted by Multiple Therapeutic Areas
8.6.2 Importance of DNA Hydroxymethylation
8.6.3 Sirtuins: Undergoing Limited Research
8.6.4 Histone Methyltranferase
8.6.4.1 Lysine Methyltranferase
8.6.4.2 Domainex: Development of HMT Inhibitor
8.6.4.3 Protein Arginine Methyltransferases: The Need for Improved Potency
8.6.4.4 Lysine Demethylases: Potential Cancer Treatment Target
9. Epigenetic Therapies, Diagnostics and Related Technologies: Industry and Market Trends 2014-2024
9.1 Epigenetic Therapies, Technologies and Diagnostics: Strengths and Weaknesses 2014-2024
9.1.1 Understanding Epigenetic Markers and Mechanisms
9.1.2 Specificity of Marketed Epigenetic Therapies
9.2 Epigenetics Therapies, Technologies and Diagnostics Market Opportunities and Threats 2014-2024
9.2.1 The Important Role of Translational Research
9.2.2 Development of Companion Diagnostics in Conjunction with Therapies
9.2.3 Rich Therapeutic and Diagnostic Pipelines
9.2.4 Combination Therapy with Epigenetic Drugs Show Promise
9.2.5 Epigenetic Drugs to Succeed Drug Resistance
9.2.6 Therapy Target Scope besides HDAC and DNMT Inhibition
9.3 Epigenetics Therapies, Technologies and Diagnostics: STEP Analysis 2014-2024
9.4 Social Factors Affecting Epigenetic Product Development
9.4.1 The Influence of Environment
9.4.2 The Role of Epigenetics in Ageing and Diseases
9.4.2.1 Increasing Prevalence of Global Disease to Drive Epigenetics Market Growth
9.4.3 Targeting Orphan Diseases and Patient Subpopulations
9.4.4 Use of Epigenetics in Personalised and Stratified Medicine
9.5 Advancing Epigenetic Technologies to Support Epigenetic Research
9.5.1 NGS: Improving the Quality of Epigenetic Research
9.5.2 Epigenetics to Help Drive Stem Cell Research Development
9.5.3 Complementary and Competing Forces
9.5.3.1 Genomics
9.5.3.2 Proteomics
9.5.3.3 Metabolomics
9.6 Economic Factors
9.6.1 Recent Developments Helped Reduce Costs in Epigenetic Research
9.6.2 Importance of Big Pharma in Epigenetic Markets 2014-2024
9.6.2.1 Pfizer
9.6.2.2 Novartis
9.6.2.3 GSK: Part of Multiple Agreements in Epigenetics
9.6.3 Valuable Licensing Deals in Epigenetics
9.6.4 Epigenetic Business Models
9.7 Political Issues
9.7.1 Ethics in Epigenetic Research
9.7.2 Global Collaboration to Expedite Market Growth
9.7.2.1 Structural Genome Consortium
9.7.2.2 Roadmap Epigenomics Project (NIH)
9.7.2.3 International Human Epigenome Consortium
9.7.2.4 Blueprint Project
10. Research Interview
10.1 Interview with Dr Eric Marcotte, Strategic Lead, Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC)
10.1.1 Canadian Institute of Health Research: Interest in Epigenetics
10.1.2 Canadian Epigenetic Therapy Market
10.1.3 Prominent Epigenetic Therapeutic Areas in the Future
10.1.4 Promising New Epigenetic Therapy and Diagnostics
10.1.5 Future of Canadian Epigenetics Market
10.1.6 CIHR and JST Partnership Outcome
11. Conclusions from the Research and Analysis
11.1 Therapies Submarket Accounts for Most of the Epigenetic Market Revenues in 2013
11.2 Growth Expected in All Submarkets of the Epigenetic Market 2014-2024
11.2.1 Developed National Pharma Markets to Lead, 2014-2024
11.3 Many Opportunities Exist in the Epigenetics Industry and Market
【レポート販売概要】
■ タイトル:世界におけるエピジェネティクスの研究開発、治療薬、診断製品市場■ 英文:Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024
■ 発行日:2014年6月
■ 調査会社:visiongain
■ 商品コード:VISG409050
■ 調査対象地域:グローバル
- 世界の軍用固定翼航空機の市場動向2013-2023:市場規模及び成長要因The global military aircraft market is estimated to value US$66.2 billion in 2013. The market consists of six categories of aircraft: multi-role, transport, attack, reconnaissance and surveillance, bombers, and training. The value of the global military aircraft market is expected to increase at a CAGR of 2.54% during the forecast period, to reach US$85 billion by 2023.
- 口蹄疫(FMD)用ワクチンの世界市場2017-2021ABSTRACTAbout Foot and Mouth Disease Vaccine FMD is a severe and contagious viral disease found in cloven-hoofed animals. FMD virus leads to illness in cows, sheep, pigs, goats, deer, and other animals with divided hooves. Animals with FMD will have fever and blisters on the tongue, lips, mammary glands, in and around the mouth, and around the hooves. These blisters pop and turn into red areas cal …
- パルミチン酸ビタミンAの世界市場2015Vitamin A Palmitate (CAS 79-81-2) Market Research Report 2015 aims at providing comprehensive data on Vitamin A Palmitate market globally and regionally (Europe, Asia, North America, Latin America etc.) The report includes Vitamin A Palmitate description, covers its application areas, manufacturing methods, patterns. It captures Vitamin A Palmitate market trends, pays close attention to Vitamin A …
- MHCV(中型/大型商用車)の世界市場2015-2019About commercial vehicles Commercial vehicles include light, medium, and heavy commercial vehicles. Light commercial vehicles have a GVWR of below 14,000 lb; medium commercial vehicles, have a GVWR of between 14,001 and 26,000 lb; and heavy vehicles (comprising trucks, commercial vehicles, buses, and coaches) have a GVWR greater than 26,001 lb. Technavio's analysts forecast the global MHCV market …
- 腹部脂胖症(Abdominal Obesity):グローバル臨床試験レビュー(2014年上半期)Abdominal Obesity Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Abdominal Obesity Global Clinical Trials Review, H1, 2014" provides data on the Abdominal Obesity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Abdominal Obesity. It includes an overview of the trial numbers and their recruitment s …
- 自動車用エレクトロニクスの世界市場:コンポーネント別(ECU、通電デバイス、センサー)、アプリケーション別(安全システム、ADAS、ボディエレクトロニクス)、販売チャネル別、セグメント予測The global automotive electronics market size is expected to reach USD 410.13 billion by 2025 at a CAGR of 8.7% over the forecast period, according to a study conducted by Grand View Research, Inc. Stringent government regulations regarding fuel emission standards along with growing inclusion of road safety systems and demand for state-of-the-art vehicles are anticipated to drive the market. Techn …
- 世界の音響補強市場:製品種類別(マイク、プロ用スピーカー、オーディオミキサー、パワーアンプ)、フォーマット別(デジタル、アナログ)、エンドユーザー別(企業、教育、大規模会場&イベント、ホスピタリティ)、地域別“The sound reinforcement market is projected to grow at a CAGR of 3.2% from 2019 to 2024.” The sound reinforcement market is expected to grow from USD 7.3 billion in 2019 to USD 8.5 billion by 2024; it is expected to grow at a CAGR of 3.2% from 2019 to 2024. The growth of the sound reinforcement market can be attributed to the increasing demand for professional audio devices from corporate and edu …
- グライコミクス/糖鎖生物学の世界市場分析:製品別(酵素、キット、試薬、機器)、用途別(創薬および開発、診断)、エンドユーザー別、セグメント予測、2014-2025The global glycomics/glycobiology market is expected to reach USD 2.1 billion by 2025, according to a new report by Grand View Research, Inc. Increasing investment in R&D by research institutes and pharmaceutical & biotechnology companies has been a major factor driving market growth. In addition, technological advancement has led to increased demand for advanced glycomics products for drug discov …
- Kinder Morgan Energy Partners, L.P.社の石油・ガス開発・生産動向及びコスト分析(2013年)Kinder Morgan Energy Partners, L.P. Oil & Gas Exploration and Production Operations and Cost Analysis - 2013 Summary Kinder Morgan Energy Partners, L.P. (KMP) is a pipeline transportation and energy storage company. KMP's pipelines transport natural gas, crude oil, refined petroleum products, condensate, CO2 and other associated products, and the company's terminals store petroleum products, ethan …
- 世界の海および国境セキュリティ市場(2014 – 2024)Summary The Global Maritime and Border Security Market 2014-2024 Report published by Strategic Defence Intelligence, provides readers with a detailed analysis of both historic and forecast global industry values, factors influencing demand, the challenges faced by industry participants, analysis of industry leading companies, and key news. Key Findings • The global maritime and border security mar …
- アメリカの魚油製品市場About Fish Oil Products in the US Fish oil is derived from tissues of oily fish species and contains a high percentage of long chain omega-3 fatty acids, such as EPA and DHA. These omega-3 fatty acids are essential nutrients for humans and animals. Fish oil is mainly used as a feed ingredient in many animal and human nutritional applications that include aquaculture feed, pharmaceuticals, animal n …
- 酢酸ブチル(BAC)の世界市場動向及び予測2015The present report is an essential resource for a one looking for detailed information on the world butyl acetate market. The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries. In addition to the analytical part, the report provides a range of tables and figures which all together give a true ins …
- 世界エンターテインメント産業におけるアニメーション及びデザインソフトウェア市場動向(2012-2016)TechNavio's analysts forecast the Global Animation and Design Software market in the Entertainment industry to grow at a CAGR of 21.10 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing adoption of 3D animation software. The Global Animation and Design Software market in the Entertainment industry has also been witnessing the development …
- 転移性移行尿路上皮癌:グローバル臨床試験レビュー(2014年上半期)Metastatic Transitional (Urothelial) Tract Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Metastatic Transitional (Urothelial) Tract Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Transitional (Urothelial) Tract Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical t …
- Associated Electric Cooperative Inc.:発電所及びSWOT分析2013Associated Electric Cooperative Inc. - Power Plants and SWOT Analysis, 2013 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services. Scope - Major Power Plants (assets) …